Dr. Swords received his medical degree from the National University of Ireland, Galway, in 2000. He completed fellowship training in hematology with the Royal College of Pathology, London (2008). He then pursed additional fellowship training in experimental therapeutics at the University of Texas Health Science Center San Antonio, followed by his PhD thesis which focused on post translational modification pathways in AML. In 2012, he joined the University of Miami to lead the adult leukemia program at that institution. In 2018, he moved to AbbVie Pharmaceuticals as a medical director, where he supported the development of venetoclax in myeloid malignancies.